AMS LSE Week ended 07 Aug 2026

Weekly Investor Report

Advanced Medical Solutions Group plc · Healthcare · Medical Instruments & Supplies

Open interactive chart View report data
Latest close 281.0 GBP
0.4% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 20.6% above the Trend Line and sits at 96.4% of its 52-week range. The latest completed week returned 0.4%, after a 0.9% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 54/100. Near-term considerations: price is close to its 52-week high.

Setup score 65 out of 100
Latest Close 281.0 GBP 7 Aug 2026
1W Return 0.4% latest completed week
4W Return 0.9% short-term follow-through
12W Return 13.8% quarterly tape
Trend Breadth 73.1% 38 of 52 weeks active
Volume Ratio 1.2x vs 13-week average
What is working
  • The trend backdrop is active with a 14-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 41.71% based on similar historical setup states.
  • 1 reversal markers appear in the recent smart-money tape.
  • Recent volatility is running well above the one-year baseline.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.4% Latest completed week; four-week move 0.9%. Indicator stack 85/73 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 41.71% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 54/100 11 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 20.6% above the Trend Line and sits at 96.4% of its 52-week range. The latest completed week returned 0.4%, after a 0.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.2x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7912-week average 0.61

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership8/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.79Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers11 reversal markers

No recent accumulation markers. 1 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 0.9% over four weeks, 13.8% over 12 weeks, and 32.6% over one year. The current trend has remained active for 14 consecutive weeks.

Performance by holding period

1W0.4%
4W0.9%
12W13.8%
26W29.5%
52W32.6%
Active trend streak14 weeks
Active weeks in one year38
Trend breadth73.1%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.21Latest activity-pressure read.
Pressure change16.2%Four-week change in activity pressure.
Leadership15.19Latest relative-leadership reading.
RS change-23.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Dec 2025 Field coverage 91% Model confidence 72%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength42/100Blend of value, momentum, and quality. Underlying universe rank 59; rank 1 is best.
Value5/100Relative valuation strength. Underlying universe rank 96; rank 1 is best.
Quality82/100Profitability and accounting quality. Underlying universe rank 19; rank 1 is best.
Momentum92/100Medium-term price momentum. Underlying universe rank 9; rank 1 is best.
Growth96/100Revenue and earnings growth. Underlying universe rank 5; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework19/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
61.4x
Price divided by trailing earnings.
Price / sales
2.7x
Market value relative to trailing revenue.
EV / EBITDA
15.4x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
3.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
53.4%
Gross profit retained from each unit of revenue.
Operating margin
12.4%
Operating profit retained from revenue.
Free-cash-flow margin
8.7%
Free cash flow generated from revenue.
Return on invested capital
6.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
29.0%
Latest one-year revenue growth.
EPS growth
39.2%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
86.0%
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
1.0%
Cash dividends relative to market value.
Buyback yield
-0.1%
Net share repurchases relative to market value.
Shareholder yield
1.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment54/100

Weighted news tone is neutral across 11 relevant articles.

1 positive · 10 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-1.2%Distance below the 52-week high.
13-week volatility6.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2612 weeks finished lower.
Best week+19.4%Week of 26 Jun.
Worst week-9.9%Week of 22 May.
Latest week+0.4%Week of 7 Aug.

Shape of recent returns

Strong gains6
Modest gains6
Flat weeks2
Modest losses9
Sharp losses3
Recent vol6.6%13-week weekly-return volatility.
Base vol4.6%52-week weekly-return volatility.
Up/down split26/23Count of positive and negative weeks in the 52-week window.
Average skew3.7% / -2.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape67/100

Trend, activity pressure, participation, and risk combine to a 67/100 tape read.

 Indicator analysis79/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 8/12.

Activity pressure 0.79; 1 reversal markers Next-Week ExpectancyNegative 41.71%

Next-week expectancy is negative with a 41.71% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors54/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 87; Small Cap Core rank 94 SVQF19/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 212.0 of 260 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment54/100

Weighted news tone is neutral across 11 relevant articles.

Form 8.5 (EPT/RI)-Advanced Medical Solutions Group Plc Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 2026281.0 GBP0.4%233.0 GBP214.3 GBP1.2115.1914.2MOn
31 Jul 2026280.0 GBP0.0%231.0 GBP214.1 GBP1.3015.3712.4MOn
24 Jul 2026280.0 GBP0.4%229.0 GBP213.9 GBP1.3317.1517.5MOn
17 Jul 2026279.0 GBP0.2%226.9 GBP213.6 GBP1.2918.6213.6MOn
10 Jul 2026278.5 GBP-0.9%224.8 GBP213.4 GBP1.0419.8820.5MOn
3 Jul 2026281.0 GBP0.2%222.4 GBP213.1 GBP0.6619.28596.0KOn
26 Jun 2026280.5 GBP19.4%220.6 GBP212.7 GBP0.3821.318.6MOn
19 Jun 2026235.0 GBP9.8%218.5 GBP212.3 GBP0.183.262.2MOn
12 Jun 2026214.0 GBP-1.4%217.7 GBP212.3 GBP0.30-7.021.3MOn
5 Jun 2026217.0 GBP-0.9%217.6 GBP212.4 GBP0.59-5.091.4MOn
29 May 2026219.0 GBP-1.6%217.5 GBP212.5 GBP0.81-4.878.2MOn
22 May 2026222.5 GBP-9.9%217.4 GBP212.6 GBP1.03-4.0045.0MOn
15 May 2026247.0 GBP-1.2%217.3 GBP212.6 GBP1.149.306.1MOn
8 May 2026250.0 GBP4.2%216.6 GBP212.7 GBP1.0610.392.9MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context